RCUS

Arcus Biosciences Inc

RCUS, USA

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

https://www.arcusbio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RCUS
stock
RCUS

Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $30 富途牛牛

Read more →
RCUS
stock
RCUS

RCUS Stock Down on Decision to Discontinue GILD Partnered Study Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$33.2222

Analyst Picks

Strong Buy

8

Buy

3

Hold

2

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.26

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-30.96 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.86 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-373.08 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.23

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 67.00% of the total shares of Arcus Biosciences Inc

1.

BlackRock Inc

(10.7656%)

since

2025/06/30

2.

Vanguard Group Inc

(6.1601%)

since

2025/06/30

3.

Point72 Asset Management, L.P.

(5.6061%)

since

2025/06/30

4.

iShares Core S&P Small-Cap ETF

(3.7878%)

since

2025/08/31

5.

Woodline Partners LP

(3.7583%)

since

2025/06/30

6.

Suvretta Capital Management, LLC

(3.466%)

since

2025/06/30

7.

State Street Corp

(3.4114%)

since

2025/06/30

8.

FMR Inc

(2.4178%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(1.9808%)

since

2025/07/31

10.

iShares Russell 2000 ETF

(1.5626%)

since

2025/08/31

11.

Dimensional Fund Advisors, Inc.

(1.5596%)

since

2025/06/30

12.

Siren, L.L.C.

(1.5147%)

since

2025/06/30

13.

Geode Capital Management, LLC

(1.4999%)

since

2025/06/30

14.

Morgan Stanley - Brokerage Accounts

(1.381%)

since

2025/06/30

15.

BNP Paribas Investment Partners SA

(1.3114%)

since

2025/06/30

16.

Sofinnova Ventures

(1.1425%)

since

2025/06/30

17.

SPDR® S&P Biotech ETF

(1.1297%)

since

2025/08/31

18.

Fidelity Select Biotechnology

(1.1164%)

since

2025/07/31

19.

RA Capital Management, LLC

(1.0677%)

since

2025/06/30

20.

Wellington Management Company LLP

(0.8795%)

since

2025/06/30

21.

Fidelity Select Pharmaceuticals Port

(0.8019%)

since

2025/07/31

22.

Jacobs Levy Equity Management, Inc.

(0.7566%)

since

2025/06/30

23.

BNP Paribas US Small Cap ClassicC

(0.7426%)

since

2025/07/31

24.

Millennium Management LLC

(0.733%)

since

2025/06/30

25.

Charles Schwab Investment Management Inc

(0.7298%)

since

2025/06/30

26.

Vanguard Small Cap Index

(0.7241%)

since

2025/07/31

27.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7013%)

since

2025/07/31

28.

Northern Trust Corp

(0.6495%)

since

2025/06/30

29.

Fidelity Small Cap Index

(0.649%)

since

2025/06/30

30.

Goldman Sachs Group Inc

(0.6089%)

since

2025/06/30

31.

BNP Paribas Health Cr Innovtr Cl Cap

(0.573%)

since

2025/07/31

33.

iShares S&P Small-Cap 600 Growth ETF

(0.5469%)

since

2025/08/31

34.

Merchfondo FI

(0.4604%)

since

2025/08/31

35.

iShares Russell 2000 Growth ETF

(0.4185%)

since

2025/08/31

36.

Vanguard Small Cap Growth Index Inv

(0.4069%)

since

2025/07/31

37.

iShares Biotechnology ETF

(0.3599%)

since

2025/08/31

38.

Vanguard Explorer Inv

(0.3568%)

since

2025/06/30

39.

Macquarie Healthcare I

(0.3562%)

since

2025/07/31

40.

Fidelity Extended Market Index

(0.3471%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.19

Latest Release

Date

2025-09-30

EPS Actual

-1.27

EPS Estimate

-1.28

EPS Difference

0.01

Surprise Percent

0.7813%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.